Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bioanalytical Systems, Inc.    BASI

BIOANALYTICAL SYSTEMS, INC.

(BASI)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Bioanalytical : I.M. (Gina) Grossi, Ph.D., Joins Inotiv as Vice President of Toxicology to Drive Growth of Expanding Toxicology Business

08/11/2020 | 08:33am EST

WEST LAFAYETTE, Ind., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“Inotiv”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, announced today that I.M. (Gina) Grossi, Ph.D., has joined the Company as Vice President, Toxicology, effective August 10, 2020. Dr. Grossi joins as the Company continues to invest in people and facilities to support the growing demand for Inotiv services.

Inotiv's philosophy, "Expect More," reflects a broadly capable, right-sized CRO with a strong commitment to client-focused service. Dr. Grossi's track record of successfully managing a range of research activities and related financials, coupled with her background in developing and cultivating client relationships, is expected to blend seamlessly with the Company's vision, mission and culture. Dr. Grossi will be responsible for driving the further growth of Inotiv's Evansville, Indiana, facility—a site that has seen a recent state-of-the-art expansion and significant upgrades to the facility.

"I couldn't be more pleased to welcome Dr. Grossi to the Inotiv team," said Philip Downing, the Company’s Sr. Vice President, Nonclinical Services. "Dr. Grossi is an accomplished industry leader with a history of success fueled by establishing policies and directing initiatives to facilitate managed growth of laboratory operations. With Dr. Grossi's significant experience and leadership in designing and managing preclinical development projects supporting INDs, nonclinical and clinical development programs, she is a great fit to guide and elevate our evolving operations and service offerings, and to inspire our teams to continuously innovate and deliver value and a superlative experience to our clients. I look forward to seeing the positive impact she will have on our organization."

Prior to joining Inotiv, Dr. Grossi provided independent consulting services for laboratory animal facility operations, and held scientific leadership positions with RTI Health Solutions, RTI International, Battelle Memorial Institute, Liberty Research, Inc., and most recently, Chimerix, Inc., as Director of Toxicology. Dr. Grossi holds a B.S. in Biology/Chemistry from Central Michigan University, an M.B.A. certification in Business Management from The Ohio State University, and a Ph.D. in Cancer Biology from Wayne State University School of Medicine in Detroit, Michigan. Dr. Grossi is a member of the American College of Toxicology (ACT), the Society of Toxicology (SOT), the North Carolina Chapter of the Society of Toxicology (NCSOT) and the American Society for Microbiology (ASM).

“I am delighted to join the Inotiv team and am honored to be part of its broad spectrum of scientific expertise in drug development,” said Dr. Grossi. "It is invigorating to be part of a growing company that is responsive to evolving industry demands and supports an efficient progression of client development goals. I look forward to joining our stakeholders in doing things that matter."

About the Company

Bioanalytical Systems, Inc., operating as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of COVID-19 on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company Contact:
Beth A. Taylor
Chief Financial Officer
Phone: 765.497.8381
btaylor@inotivco.com


Inotiv_Logo_CMYK.png

Source: Bioanalytical Systems, Inc.

2020 GlobeNewswire, Inc., source Press Releases

All news about BIOANALYTICAL SYSTEMS, INC.
10/20BIOANALYTICAL : Andrew N. Alexander, DVM, Ph.D., MBA, DABT, Joins Inotiv as Vice..
AQ
10/20Andrew N. Alexander, DVM, Ph.D., MBA, DABT, Joins Inotiv as Vice President, P..
GL
09/18BIOANALYTICAL SYSTEMS INC : Results of Operations and Financial Condition, Finan..
AQ
09/16BIOANALYTICAL SYSTEMS INC : Regulation FD Disclosure (form 8-K)
AQ
09/09BIOANALYTICAL : BASi to Participate in H.C. Wainright Investment Conference
AQ
09/09BASi to Participate in H.C. Wainright Investment Conference
GL
08/14BIOANALYTICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
08/14BASi Releases Earnings for Third Quarter of Fiscal 2020
GL
08/11BIOANALYTICAL : I.M. (Gina) Grossi, Ph.D., Joins Inotiv as Vice President of Tox..
AQ
07/15MERCK : to Invest EUR18 Million in Swiss Laboratory
DJ
More news
Financials (USD)
Sales 2019 43,6 M - -
Net income 2019 -0,79 M - -
Net Debt 2019 16,0 M - -
P/E ratio 2019 -44,9x
Yield 2019 -
Capitalization 71,3 M 71,3 M -
EV / Sales 2018 0,96x
EV / Sales 2019 1,23x
Nbr of Employees 317
Free-Float 65,4%
Chart BIOANALYTICAL SYSTEMS, INC.
Duration : Period :
Bioanalytical Systems, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOANALYTICAL SYSTEMS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers
NameTitle
Robert Leasure President, Chief Executive Officer & Director
Gregory C. Davis Chairman
Beth A. Taylor Chief Financial Officer & Vice President-Finance
Richard Allen Johnson Independent Director
Wendy Perrow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOANALYTICAL SYSTEMS, INC.31.11%71
LONZA GROUP AG55.15%44 901
MODERNA, INC.458.18%43 204
CELLTRION, INC.82.04%39 811
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832